| Identification | Back Directory | [Name]
TERBUTALINE SULFATE | [CAS]
23031-32-5 | [Synonyms]
TERBUL
Convon
Brithine
Butalire
MONOVENT
bricanyl
BRETHINE
BUTALIRET
TERBASMIN
BRETHAIRE
Bricanyl[R]
TERBUTALIN SULFATE
TERBUTALINE SULFATE
TERBUTALINE SULPHATE
Terbutaline solution
dl-Terbutaline sulfate
TERBUTALINESULFATE,USP
TERBUTALINE HEMISULFATE
Terbutaline hemisulphate
Terbutaline heMisulfate sa
Terbutaline Sulfate (125 mg)
TERBUTALINE HEMISULFATE SALT
2-T-BUTYLAMINO-1-(3,5-DIHYDROXYPHENYL)ETHANOL
Terbutaline hemisulfate salt Solution, 100ppm
1-(3,5-dihydroxyphenyl)-2-tert-butylaminoethanolsulphate
2-tert-Butylamino-1-(3,5-dihydroxyphenyl)ethanol hemisulfate
2-T-BUTYLAMINO-1-[3,5-DIHYDROXYPHENYL]ETHANOL HEMISULFATE SALT
2-(tert-Butylamino)-1-(3,5-dihydroxyphenyl)ethanol sulfate (2:1)
alpha-((tert-butylamino)methyl)-3,5-dihydroxy-benzylalcohosulfate(2:1)
3-benzenediol,5-(2-((1,1-dimethylethyl)amino)-1-hydroxyethyl)-sulfate(2
alpha-((tert-butylamino)methyl)-3,5-dihydroxybenzylalcoholsulfate(2:1)(sa
1,3-Benzenediol, 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-, sulfate (2:1)
3,5-Dihydroxy-α-[[(1,1-dimethylethyl)amino]methyl]benzyl alcohol·0.5sulfuric acid
1,3-Benzenediol, 5-2-(1,1-dimethylethyl)amino-1-hydroxyethyl-, sulfate (2:1) (salt)
Benzyl alcohol, a-[(tert-butylamino)methyl]-3,5-dihydroxy-, sulfate (2:1) (salt) (8CI)
5-[2-[(1,1-Dimethylethyl)amino]-1-hydroxyethyl]-1,3-benzenediol sulfate (2:1) (salt)
1,3-Benzenediol, 5-[2-[(1,1-dimethylethyl)amino]-1-hydroxyethyl]-, sulfate (2:1) (salt) (9CI)
2-tert-Butylamino-1-(3,5-dihydroxyphenyl)ethanol, Brethaire, Brethine, Butaliret, Monovent, Terbasmin, Terbul | [EINECS(EC#)]
245-386-3 | [Molecular Formula]
C24H40N2O10S | [MDL Number]
MFCD00079584 | [MOL File]
23031-32-5.mol | [Molecular Weight]
548.65 |
| Chemical Properties | Back Directory | [Appearance]
Crystalline Powder | [Melting point ]
246-248°C | [density ]
1.1840 (rough estimate) | [refractive index ]
1.6900 (estimate) | [storage temp. ]
-20?C Freezer | [solubility ]
H2O: soluble100mg/mL, clear to slightly hazy, colorless to yellow | [form ]
neat | [pka]
pKa1 8.8, pKa2 10.1, pKa3 11.2(at 25℃) | [color ]
White to Off-White | [InChI]
InChI=1S/2C12H19NO3.H2O4S/c2*1-12(2,3)13-7-11(16)8-4-9(14)6-10(15)5-8;1-5(2,3)4/h2*4-6,11,13-16H,7H2,1-3H3;(H2,1,2,3,4) | [InChIKey]
KFVSLSTULZVNPG-UHFFFAOYSA-N | [SMILES]
C1(=CC(=CC(O)=C1)O)C(O)CNC(C)(C)C.C1(=CC(=CC(O)=C1)O)C(O)CNC(C)(C)C.S(=O)(=O)(O)O |
| Hazard Information | Back Directory | [Chemical Properties]
Crystalline Powder | [Uses]
A B-Adrenergic receptor agonist. A Bronchodilator | [Uses]
Anti Asthmatic | [Uses]
betaadrenergic agonist, bronchodilator | [Description]
Terbutaline is the N-t-butyl analogue of metaproterenol and, as such, would be expected to have a more potent β2-selectivity. When compared to metaproterenol, terbutaline has a threefold greater potency at the β2-receptor. Like metaproterenol, it is resistant to COMT and slowly metabolized by MAO, therefore having good oral bioavailability with similar onset and duration. Terbutaline is available as tablets and solutions for injection and inhalation. Adverse effects are similar to other direct-acting β2-selective agonists, however, with a greater incidence of palp | [Originator]
Bricanyl,Pharma-Stern,W. Germany,1971 | [Definition]
ChEBI: Terbutaline sulfate is an ethanolamine sulfate salt. It is functionally related to a terbutaline. | [Manufacturing Process]
To a solution of 32 g of benzyl-t-butylamine in 300 ml of absolute ethanol at
reflux temperature was added 32 g of 3,5-dibenzyloxy-?-bromoacetophenone
in 10 ml of dry benzene. The mixture was refluxed for 20 hours and then
evaporated. When absolute ether was added to the residue, benzyl-tbutylamine
hydrobromide was precipitated. The precipitated compound was
filtered off and to the filtrate was added an excess of 2 N sulfuric acid. This
caused precipitation of the hydrogen sulfate of 3,5-dibenzyloxy-?-(benzyl-tbutylamino)-
acetophenone which was recrystallized from acetone/ether. If the product is crystallized from different organic solvents, the melting point will
vary with the type and amount of solvent of crystallization, but the product
can be used directly for hydrogenation.
15 g of 3,5-dibenzyloxy-?-(benzyl-t-butylamino)-acetophenone hydrogen
sulfate in 200 ml of glacial acetic acid were hydrogenated in a Parr pressure
reaction apparatus in the presence of 1.5 g of 10% palladium charcoal at
50°C and 5 atmospheres pressure. The reaction time was 5 hours. The
catalyst was filtered off, the filtrate was evaporated to dryness and the
hydrogen sulfate of 1-(3',5'-dihydroxyphenyl)-2-(t-butylamino)-ethanol was
received. This compound is hygroscopic, but it can be transformed into a
nonhygroscopic sulfate in the following manner.
The hydrogen sulfate was dissolved in water and the pH of the solution was
adjusted to 5.6 (pH-meter) with 0.1 N sodium hydroxide solution. The water
solution was evaporated to dryness and the residue dried with absolute
ethanol/benzene and once more evaporated to dryness. The remaining crystal
mixture was extracted in a Soxhlet extraction apparatus with absolute
methanol. From the methanol phase the sulfate of 1-(3',5'-dihydroxyphenyl)-
2-(t-butylamino)-ethanol crystallized. Melting point 246°C to 248°C. | [Brand name]
Terbutaline is INN and
BAN. | [Therapeutic Function]
Bronchodilator | [Clinical Use]
Beta2
-adrenoceptor agonist:
Reversible airways obstruction | [Veterinary Drugs and Treatments]
Terbutaline is used as a bronchodilating agent in the adjunctive
treatment of cardiopulmonary diseases (including tracheobronchitis,
collapsing trachea, pulmonary edema, and allergic bronchitis)
in small animals. It may be of some benefit in treating bradyarrhythmias
in dogs and cats.
Terbutaline has been used occasionally in horses for its bronchodilating
effects, but adverse effects, short duration of activity after
IV administration and poor oral absorption have limited its use.
It has been shown to be useful as a diagnostic agent to diagnose
anhidrosis in horses after intradermal injection.
Oral and intravenous terbutaline has been used successfully in
humans for the inhibition of premature labor clinical signs. | [Drug interactions]
Potentially hazardous interactions with other drugs
Effect may be diminished by beta-blockers.
Theophylline: increased risk of hypokalaemia. | [Metabolism]
Terbutaline undergoes extensive first-pass metabolism
by sulphate (and some glucuronide) conjugation in the
liver and the gut wall. It is excreted in the urine and faeces
partly as the inactive sulphate conjugate and partly as
unchanged terbutaline, the ratio depending upon the
route by which it is given. |
| Safety Data | Back Directory | [Hazard Codes ]
Xn | [Risk Statements ]
42/43-63 | [Safety Statements ]
26-36 | [WGK Germany ]
3
| [RTECS ]
DN9000000
| [HS Code ]
2922504500 | [Toxicity]
dog,LD50,intravenous,116mg/kg (116mg/kg),Kiso to Rinsho. Clinical Report. Vol. 6, Pg. 757, 1972. |
|
|